- Home
- GGT vs SKYE Comparison
GGT vs SKYE Comparison
Compare GGT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGT
- SKYE
- Stock Information
- Founded
- GGT 1994
- SKYE 2012
- Country
- GGT United States
- SKYE United States
- Employees
- GGT N/A
- SKYE N/A
- Industry
- GGT Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GGT Finance
- SKYE Health Care
- Exchange
- GGT Nasdaq
- SKYE Nasdaq
- Market Cap
- GGT 134.4M
- SKYE 115.9M
- IPO Year
- GGT N/A
- SKYE N/A
- Fundamental
- Price
- GGT $4.27
- SKYE $3.98
- Analyst Decision
- GGT
- SKYE Buy
- Analyst Count
- GGT 0
- SKYE 6
- Target Price
- GGT N/A
- SKYE $16.60
- AVG Volume (30 Days)
- GGT 59.7K
- SKYE 2.2M
- Earning Date
- GGT 01-01-0001
- SKYE 08-08-2025
- Dividend Yield
- GGT 15.56%
- SKYE N/A
- EPS Growth
- GGT N/A
- SKYE N/A
- EPS
- GGT 0.83
- SKYE N/A
- Revenue
- GGT N/A
- SKYE N/A
- Revenue This Year
- GGT N/A
- SKYE N/A
- Revenue Next Year
- GGT N/A
- SKYE N/A
- P/E Ratio
- GGT $6.90
- SKYE N/A
- Revenue Growth
- GGT N/A
- SKYE N/A
- 52 Week Low
- GGT $4.32
- SKYE $1.14
- 52 Week High
- GGT $7.00
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- GGT 69.23
- SKYE 60.88
- Support Level
- GGT $3.75
- SKYE $3.65
- Resistance Level
- GGT $4.06
- SKYE $4.75
- Average True Range (ATR)
- GGT 0.05
- SKYE 0.71
- MACD
- GGT 0.04
- SKYE 0.00
- Stochastic Oscillator
- GGT 88.78
- SKYE 48.55
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.